GlaxoSmithKline’s Arexvy vaccine shows promise in protecting adults aged 50-59 against RSV
In a significant development, GlaxoSmithKline (GSK) announced promising results from a late-stage clinical trial for their vaccine, Arexvy, which exhibits the potential to protect adults [more…]